Supernus Pharmaceuticals Inc (SUPN)

Pretax margin

Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020
Earnings before tax but after interest (EBT) (ttm) US$ in thousands 97,870 72,478 37,424 -6,005 2,769 36,892 26,559 55,010 60,716 27,654 57,058 76,969 73,175 110,817 134,568 150,543 168,648 169,867 156,746 152,282
Revenue (ttm) US$ in thousands 661,817 654,387 632,578 598,906 607,521 619,414 641,163 674,751 673,056 651,277 618,187 585,808 560,079 545,016 551,524 536,576 506,717 465,383 418,476 402,257
Pretax margin 14.79% 11.08% 5.92% -1.00% 0.46% 5.96% 4.14% 8.15% 9.02% 4.25% 9.23% 13.14% 13.07% 20.33% 24.40% 28.06% 33.28% 36.50% 37.46% 37.86%

December 31, 2024 calculation

Pretax margin = EBT (ttm) ÷ Revenue (ttm)
= $97,870K ÷ $661,817K
= 14.79%

The pretax margin of Supernus Pharmaceuticals Inc has experienced fluctuations over the period from March 31, 2020, to December 31, 2024. Initially, the company demonstrated a strong pretax margin of around 37-38% in the first half of 2020. However, there was a gradual decline in the pretax margin, dropping to 13.07% by December 31, 2021.

Subsequently, there was a notable decrease in the pretax margin to 9.02% by December 31, 2022, before a slight increase to 8.15% by March 31, 2023. The trend continued with further declines, reaching a low of 0.46% by December 31, 2023, and even turning negative at -1.00% by March 31, 2024.

However, there was a significant turnaround in the pretax margin in the latter part of 2024, with a substantial increase to 14.79% by December 31, 2024. This improvement indicates a potential recovery in the profitability of the company.

Overall, the pretax margin of Supernus Pharmaceuticals Inc exhibited volatility and fluctuations during the period under analysis, with both highs and lows in profitability during different quarters.